Adverse effects in the treatment of Parkinson's disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be managed by dose reduction, medication substitution and specific counteractive measures. Anticholinergics frequently cause cognitive or autonomic symptoms while ergot-derived dopamine agonists carry unique, albeit rare, risks of fibrotic, vasoconstrictive and dermatological side effects. Current areas of controversy include: dopamine agonist-induced sleep attacks, increased mortality with the combination of selegiline and levodopa and the association of levodopa with melanoma.

Original languageEnglish
Pages (from-to)105-118
Number of pages14
JournalExpert Review of Neurotherapeutics
Volume2
Issue number1
DOIs
StatePublished - Jun 24 2002

Fingerprint

Levodopa
Parkinson Disease
Dopamine Agonists
Antiparkinson Agents
Selegiline
Orthostatic Hypotension
Sleep Stages
Dyskinesias
Cholinergic Antagonists
Nausea
Vomiting
Melanoma
Edema
Sleep
Therapeutics
Mortality
Pharmaceutical Preparations

Keywords

  • Anticholinergics
  • COMT inhibitors
  • Dopamine agonists
  • Malignant melonoma
  • MAO-B inhibitors
  • Parkinson's disease
  • Side effects

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Adverse effects in the treatment of Parkinson's disease. / Singer, Carlos.

In: Expert Review of Neurotherapeutics, Vol. 2, No. 1, 24.06.2002, p. 105-118.

Research output: Contribution to journalArticle

@article{4356a0d645ee4532a0f32b4250ed4ff1,
title = "Adverse effects in the treatment of Parkinson's disease",
abstract = "Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be managed by dose reduction, medication substitution and specific counteractive measures. Anticholinergics frequently cause cognitive or autonomic symptoms while ergot-derived dopamine agonists carry unique, albeit rare, risks of fibrotic, vasoconstrictive and dermatological side effects. Current areas of controversy include: dopamine agonist-induced sleep attacks, increased mortality with the combination of selegiline and levodopa and the association of levodopa with melanoma.",
keywords = "Anticholinergics, COMT inhibitors, Dopamine agonists, Malignant melonoma, MAO-B inhibitors, Parkinson's disease, Side effects",
author = "Carlos Singer",
year = "2002",
month = "6",
day = "24",
doi = "10.1586/14737175.2.1.105",
language = "English",
volume = "2",
pages = "105--118",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Adverse effects in the treatment of Parkinson's disease

AU - Singer, Carlos

PY - 2002/6/24

Y1 - 2002/6/24

N2 - Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be managed by dose reduction, medication substitution and specific counteractive measures. Anticholinergics frequently cause cognitive or autonomic symptoms while ergot-derived dopamine agonists carry unique, albeit rare, risks of fibrotic, vasoconstrictive and dermatological side effects. Current areas of controversy include: dopamine agonist-induced sleep attacks, increased mortality with the combination of selegiline and levodopa and the association of levodopa with melanoma.

AB - Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be managed by dose reduction, medication substitution and specific counteractive measures. Anticholinergics frequently cause cognitive or autonomic symptoms while ergot-derived dopamine agonists carry unique, albeit rare, risks of fibrotic, vasoconstrictive and dermatological side effects. Current areas of controversy include: dopamine agonist-induced sleep attacks, increased mortality with the combination of selegiline and levodopa and the association of levodopa with melanoma.

KW - Anticholinergics

KW - COMT inhibitors

KW - Dopamine agonists

KW - Malignant melonoma

KW - MAO-B inhibitors

KW - Parkinson's disease

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=0036286443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036286443&partnerID=8YFLogxK

U2 - 10.1586/14737175.2.1.105

DO - 10.1586/14737175.2.1.105

M3 - Article

C2 - 19811020

AN - SCOPUS:0036286443

VL - 2

SP - 105

EP - 118

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -